Antonio Fanelli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Antonio Fanelli has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Alessandro Sciarra
Department of Maternal-Infant and Urological Sciences, “Sapienza” University of Rome, Umberto I Hospital, 00185 Rome, Italy
1 shared publication - Angelo Porreca
Urology Unit, Humanitas Gavazzeni, 24125 Bergamo, Italy
1 shared publication Anna Ricapito
Department of Urology, University of Foggia, Foggia, Italy, unifg.it
1 shared publication- Benjamin Inbeh Chung
Department of Urology, Stanford University School of Medicine, Stanford, California
1 shared publication - Biagio Barone
Department of Urology, Ospedale San Paolo, ASL NA1 Centro, 80125 Naples, Italy
1 shared publication Carlo Bettocchi
Department of Urology, University of Foggia, Foggia, Italy, unifg.it
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Urology
- Vol. 2026 (1) , 7984631
Single Epididymis Metastasis 12 Years After Radical Prostatectomy: A Case Report and Literature Review
Introduction: Metastatic spread of prostate cancer to the epididymis is exceptionally rare. Recognition is challenging because clinical and ultrasonographic findings may mimic benign or primary paratesticular lesions. Case Presentation: We describe a 71‐year‐old man who developed an isolated epididymal metastasis 12 years after radical prostatectomy for high‐risk prostate cancer. After adjuvant treatment and later biochemical recurrence managed with salvage radiotherapy and androgen deprivation therapy, prostate‐specific antigen rose to 2.2 ng/mL despite castrate testosterone levels. Choline positron emission tomography/computed tomography identified a suspicious paratesticular lesion. Scrotal ultrasound showed a cystic mass initially suggestive of a benign epididymal lesion. Surgical exploration with hydrocelectomy and excision of the epididymal mass was performed for both diagnostic and therapeutic purposes. Histology and immunohistochemistry confirmed metastatic adenocarcinoma of prostatic origin. After surgery, prostate‐specific antigen became undetectable. Conclusion: This case underlines the need to consider epididymal metastasis during follow‐up when prostate‐specific antigen rises without typical sites of relapse and supports the role of dedicated scrotal evaluation, molecular imaging, and individualized surgical management in selected patients.
- 1 January 2026
- Published by Wiley in Case Reports in Urology
- Vol. 2026 (1) , 7984631
Open AccessSingle Epididymis Metastasis 12 Years After Radical Prostatectomy: A Case Report and Literature Review
Introduction: Metastatic spread of prostate cancer to the epididymis is exceptionally rare. Recognition is challenging because clinical and ultrasonographic findings may mimic benign or primary paratesticular lesions. Case Presentation: We describe a 71‐year‐old man who developed an isolated epididymal metastasis 12 years after radical prostatectomy for high‐risk prostate cancer. After adjuvant treatment and later biochemical recurrence managed with salvage radiotherapy and androgen deprivation therapy, prostate‐specific antigen rose to 2.2 ng/mL despite castrate testosterone levels. Choline positron emission tomography/computed tomography identified a suspicious paratesticular lesion. Scrotal ultrasound showed a cystic mass initially suggestive of a benign epididymal lesion. Surgical exploration with hydrocelectomy and excision of the epididymal mass was performed for both diagnostic and therapeutic purposes. Histology and immunohistochemistry confirmed metastatic adenocarcinoma of prostatic origin. After surgery, prostate‐specific antigen became undetectable. Conclusion: This case underlines the need to consider epididymal metastasis during follow‐up when prostate‐specific antigen rises without typical sites of relapse and supports the role of dedicated scrotal evaluation, molecular imaging, and individualized surgical management in selected patients.
- Open Access
- 13 March 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (3) , 512
Bladder Cancer and Risk Factors: Data from a Multi-Institutional Long-Term Analysis on Cardiovascular Disease and Cancer Incidence
Background: Bladder cancer (BCa) is a heterogeneous disease with a variable prognosis and natural history. Cardiovascular disease (CVD), although completely different, has several similarities and possible interactions with cancer. The association between them is still unknown, but common risk factors between the two suggest a shared biology. Materials and Methods: This was a retrospective study that included patients who underwent transurethral resection of bladder tumor at two high-volume institutions. Depending on the presence of a previous history of CVD or not, patients were divided into two groups. Results: A total of 2050 patients were included, and 1638 (81.3%) were diagnosed with bladder cancer. Regarding comorbidities, the most common were hypertension (59.9%), cardiovascular disease (23.4%) and diabetes (22.4%). At univariate analysis, independent risk factors for bladder cancer were age and male sex, while protective factors were cessation of smoking and presence of CVD. All these results, except for ex-smoker status, were confirmed at the multivariate analysis. Another analysis was performed for patients with high-risk bladder cancer and, in this case, the role of CVD was not statistically significant. Conclusions: Our study pointed out a positive association between CVD and BCa incidence; CVD was an independent protective factor for BCa. This effect was not confirmed for high-risk tumors. Several biological and genomics mechanisms clearly contribute to the onset of both diseases, suggesting a possible shared disease pathway and highlighting the complex interplay of cancer and CVD. CVD treatment can involve different drugs with a possible effect on cancer incidence, but, to date, findings are still inconclusive.
- 13 March 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (3) , 512
Open AccessBladder Cancer and Risk Factors: Data from a Multi-Institutional Long-Term Analysis on Cardiovascular Disease and Cancer Incidence
Background: Bladder cancer (BCa) is a heterogeneous disease with a variable prognosis and natural history. Cardiovascular disease (CVD), although completely different, has several similarities and possible interactions with cancer. The association between them is still unknown, but common risk factors between the two suggest a shared biology. Materials and Methods: This was a retrospective study that included patients who underwent transurethral resection of bladder tumor at two high-volume institutions. Depending on the presence of a previous history of CVD or not, patients were divided into two groups. Results: A total of 2050 patients were included, and 1638 (81.3%) were diagnosed with bladder cancer. Regarding comorbidities, the most common were hypertension (59.9%), cardiovascular disease (23.4%) and diabetes (22.4%). At univariate analysis, independent risk factors for bladder cancer were age and male sex, while protective factors were cessation of smoking and presence of CVD. All these results, except for ex-smoker status, were confirmed at the multivariate analysis. Another analysis was performed for patients with high-risk bladder cancer and, in this case, the role of CVD was not statistically significant. Conclusions: Our study pointed out a positive association between CVD and BCa incidence; CVD was an independent protective factor for BCa. This effect was not confirmed for high-risk tumors. Several biological and genomics mechanisms clearly contribute to the onset of both diseases, suggesting a possible shared disease pathway and highlighting the complex interplay of cancer and CVD. CVD treatment can involve different drugs with a possible effect on cancer incidence, but, to date, findings are still inconclusive.